Duineveld C, Bouwmeester R, Wijnsma K, Bemelman F, van der Heijden J, Berger S
Kidney Int Rep. 2023; 8(4):715-726.
PMID: 37069997
PMC: 10105043.
DOI: 10.1016/j.ekir.2023.01.016.
Acosta-Medina A, Moyer A, Go R, Willrich M, Fervenza F, Leung N
Blood Adv. 2022; 7(3):340-350.
PMID: 35533258
PMC: 9881046.
DOI: 10.1182/bloodadvances.2021006416.
Infante B, Rossini M, Leo S, Troise D, Netti G, Ranieri E
Int J Mol Sci. 2020; 21(17).
PMID: 32824988
PMC: 7504691.
DOI: 10.3390/ijms21175954.
Khalifeh A, Reif M, Tolayamat B, Karanja J, Sarkar R, Toursavadkohi S
J Vasc Surg Cases Innov Tech. 2019; 5(1):7-11.
PMID: 30619982
PMC: 6313836.
DOI: 10.1016/j.jvscit.2018.08.012.
Wijnsma K, Duineveld C, Wetzels J, van de Kar N
Pediatr Nephrol. 2018; 34(11):2261-2277.
PMID: 30402748
PMC: 6794245.
DOI: 10.1007/s00467-018-4091-3.
Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice.
Modelli de Andrade L, Contti M, Nga H, Bravin A, Takase H, Viero R
PLoS One. 2017; 12(11):e0188155.
PMID: 29136640
PMC: 5685617.
DOI: 10.1371/journal.pone.0188155.
Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.
Brocklebank V, Kavanagh D
Clin Kidney J. 2017; 10(5):600-624.
PMID: 28980670
PMC: 5622895.
DOI: 10.1093/ckj/sfx081.
Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome.
Macia M, de Alvaro Moreno F, Dutt T, Fehrman I, Hadaya K, Gasteyger C
Clin Kidney J. 2017; 10(3):310-319.
PMID: 28621343
PMC: 5466111.
DOI: 10.1093/ckj/sfw115.
Complement related kidney diseases: Recurrence after transplantation.
Salvadori M, Bertoni E
World J Transplant. 2017; 6(4):632-645.
PMID: 28058212
PMC: 5175220.
DOI: 10.5500/wjt.v6.i4.632.
Critical appraisal of eculizumab for atypical hemolytic uremic syndrome.
Palma L, Langman C
J Blood Med. 2016; 7:39-72.
PMID: 27110144
PMC: 4835139.
DOI: 10.2147/JBM.S36249.
Rescue therapy with eculizumab in a transplant recipient with atypical haemolytic-uraemic syndrome.
Duran C, Blasco M, Maduell F, Campistol J
Clin Kidney J. 2015; 5(1):28-30.
PMID: 26069742
PMC: 4400444.
DOI: 10.1093/ndtplus/sfr107.
Treatment of atypical uraemic syndrome in the era of eculizumab.
Fremeaux-Bacchi V
Clin Kidney J. 2015; 5(1):4-6.
PMID: 26069738
PMC: 4400466.
DOI: 10.1093/ckj/sfr177.
Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature.
Alasfar S, Alachkar N
Front Med (Lausanne). 2015; 1:52.
PMID: 25593925
PMC: 4292050.
DOI: 10.3389/fmed.2014.00052.
Eculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndrome.
Tsai H, Kuo E
Adv Hematol. 2014; 2014:295323.
PMID: 25400666
PMC: 4221969.
DOI: 10.1155/2014/295323.
Current treatment of atypical hemolytic uremic syndrome.
Kaplan B, Ruebner R, Spinale J, Copelovitch L
Intractable Rare Dis Res. 2014; 3(2):34-45.
PMID: 25343125
PMC: 4204535.
DOI: 10.5582/irdr.2014.01001.
Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.
Kourouklaris A, Ioannou K, Athanasiou I, Panagidou A, Demetriou K, Zavros M
J Med Case Rep. 2014; 8:307.
PMID: 25219386
PMC: 4170201.
DOI: 10.1186/1752-1947-8-307.
Eculizumab: a review of its use in atypical haemolytic uraemic syndrome.
Keating G
Drugs. 2013; 73(18):2053-66.
PMID: 24249647
DOI: 10.1007/s40265-013-0147-7.
Successful treatment of DEAP-HUS with eculizumab.
Noone D, Waters A, Pluthero F, Geary D, Kirschfink M, Zipfel P
Pediatr Nephrol. 2013; 29(5):841-51.
PMID: 24249282
DOI: 10.1007/s00467-013-2654-x.
Atypical hemolytic uremic syndrome.
Kavanagh D, Goodship T, Richards A
Semin Nephrol. 2013; 33(6):508-30.
PMID: 24161037
PMC: 3863953.
DOI: 10.1016/j.semnephrol.2013.08.003.
Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses.
Sana G, Dragon-Durey M, Charbit M, Bouchireb K, Rousset-Rouviere C, Berard E
Pediatr Nephrol. 2013; 29(1):75-83.
PMID: 23868108
DOI: 10.1007/s00467-013-2558-9.
